Comparing macroscopic continuum models for rarefied gas dynamics : a new test method

We propose a new test method for investigating which macroscopic continuum models, among the many existing models, give the best description of rarefied gas flows over a range of Knudsen numbers. The merits of our method are: no boundary conditions for the continuum models are needed, no coupled governing equations are solved, while the Knudsen layer is still considered. This distinguishes our proposed test method from other existing techniques (such as stability analysis in time and space, computations of sound speed and dispersion, and the shock wave structure problem). Our method relies on accurate, essentially noise-free, solutions of the basic microscopic kinetic equation, e.g. the Boltzmann equation or a kinetic model equation; in this paper, the BGK model and the ES-BGK model equations are considered. Our method is applied to test whether one-dimensional stationary Couette flow is accurately described by the following macroscopic transport models: the Navier-Stokes-Fourier equations, Burnett equations, Grad's 13 moment equations, and the regularized 13 moment equations (two types: the original, and that based on an order of magnitude approach). The gas molecular model is Maxwellian. For Knudsen numbers in the transition-continuum regime (Kn less-than-or-equals, slant 0.1), we find that the two types of regularized 13 moment equations give similar results to each other, which are better than Grad's original 13 moment equations, which, in turn, give better results than the Burnett equations. The Navier-Stokes-Fourier equations give the worst results. This is as expected, considering the presumed accuracy of these models. For cases of higher Knudsen numbers, i.e. Kn > 0.1, all macroscopic continuum equations tested fail to describe the flows accurately. We also show that the above conclusions from our tests are general, and independent of the kinetic model used

Computing the near-wall region in gas micro- and nanofluidics: critical Knudsen layer phenomena

In order to capture critical near-wall phenomena in gas micro- and nanoflows within conventional CFD codes, we present scaled Navier-Stokes-Fourier (NSF) constitutive relations. Our scaling is mathematically equivalent to applying an 'effective' viscosity to the original constitutive relations. An expression for this 'effective' transport coefficient is obtained from the half-space Kramer's flow problem. The advantage of our model over the traditional NSF equations is that the non-equilibrium flow near to the wall (the momentum Knudsen layer) can be described. Its advantage over higher order hydrodynamic models for gas micro- and nanoflows is that the boundary conditions remain the same as required for the traditional NSF equations, so modifications to current CFD codes (provided they are already capable of modelling slip at solid surfaces) would be minimal. As an application example, we apply our model to the isothermal problem of a micro-sphere moving through a gas: we show that our model gives excellent results in the Knudsen number range Kn less than or similar to 0.1 and acceptable results up to Kn approximate to 0.25. This is much better than the traditional NSF model with non-scaled constitutive relations

Confidence-based iterative efficient large-scale stereo matching

In this study, we integrate confidence into efficient large-scale stereo (ELAS) matching to produce a more accurate approach to binocular stereo for high-resolution image matching. Elas ensures good performance in the presence of poorly textured and slanted surfaces, but one of its deficiencies is its unsatisfactory ability to capture disparity discontinuities. Our formulation explicitly models the effects of confidence as a likelihood term in a principled manner using the Bayes rule. Because it is an iterative method, we associate each point with a variable confidence value and update this value based on a given confidence updating rule. Meanwhile, complementary support points are selected from stable points whose confidence value exceeds a predefined threshold, which differs from ELAS, whose support points are matched in advance and kept unchanged in the subsequent process. Confidence also plays a vital role in avoiding expensive computation, and the adjustment of support points makes disparity estimation more flexible. Quantitative evaluation demonstrates the effectiveness and efficiency of the proposed formulation in improving the accuracy of disparity estimation

Gastrointestinal Motility and Gut Hormone Secretion in response to Shenhuang Plaster in a Postoperative Ileus Rat Model

Postoperative ileus (POI), a gastrointestinal function disorder, is a complication that arises from surgery. Shenhuang plaster (SHP) application to the Shenque acupoint (CV8) to promote the recovery of gastrointestinal function has achieved definite curative effects in clinical settings; however, the underlying pharmacological mechanism remains unknown. In this study, we evaluated the effects of SHP using a Sprague Dawley rat POI model. Then, gastrointestinal transit in different rat groups was evaluated by the movement of fluorescein-labelled dextran. Ghrelin, obestatin, motilin (MTL), and vasoactive intestinal peptide (VIP) plasma concentrations were measured via a radioimmunoassay. The expression of the ghrelin and obestatin receptors (GHS-R1α and GPR39) in the intestinal muscularis of rats in different groups was comparatively identified via western blotting. The results indicated that SHP application improved gastrointestinal motility in POI model rats. SHP application significantly increased ghrelin concentration and the expression of its receptor and inhibited obestatin concentration and the expression of its receptor in blood. Further, ghrelin concentration and the capability of gastrointestinal transit were positively correlated. Simultaneously, SHP application also promoted the secretion of other gastrointestinal motility hormones, such as MTL and VIP. Hence, these results provide evidence that SHP can promote the recovery of gastrointestinal transmission in POI rat models through regulation of ghrelin and other intestinal hormones

Protective effect and mechanism of Qingfei Paidu decoction on myocardial damage mediated by influenza viruses

Introduction: Significant attention has been paid to myocardial damage mediated by the single-stranded RNA virus. Qingfei Paidu decoction (QFPDD) has been proved to protect the damage caused by the influenza virus A/PR/8/1934 (PR8), but its specific mechanism is unclear.Methods: Molecular biological methods, together with network pharmacology, were used to analyze the effects and underlying mechanism of QFPDD treatment on PR8-induced myocardial damage to obtain insights into the treatment of COVID-19-mediated myocardial damage.Results: Increased apoptosis and subcellular damage were observed in myocardial cells of mice infected by PR8. QFPDD treatment significantly inhibited the apoptosis and subcellular damage induced by the PR8 virus. The inflammatory factors IFN-β, TNF-α, and IL-18 were statistically increased in the myocardia of the mice infected by PR8, and the increase in inflammatory factors was prevented by QFPDD treatment. Furthermore, the expression levels or phosphorylation of necroptosis-related proteins RIPK1, RIPK3, and MLKL were abnormally elevated in the group of infected mice, while QFPDD restored the levels or phosphorylation of these proteins. Our study demonstrated that HIF-1α is a key target of QFPDD in the treatment of influenza virus-mediated injury. The HIF-α level was significantly increased by PR8 infection. Both the knockdown of HIF-1α and treatment of the myocardial cell with QFPDD significantly reversed the increased inflammatory factors during infection. Overexpression of HIF-1α reversed the inhibition effects of QFPDD on cytokine expression. Meanwhile, seven compounds from QFPDD may target HIF-1α.Conclusion: QFPDD can ameliorate influenza virus-mediated myocardial damage by reducing the degree of cell necroptosis and apoptosis, inhibiting inflammatory response and the expression of HIF-1α. Thus, our results provide new insights into the treatment of respiratory virus-mediated myocardial damage

A novel chemotherapeutic sensitivity-testing system based on collagen gel droplet embedded 3D–culture methods for hepatocellular carcinoma

Abstract Background Patients suffering from advanced stage hepatocellular carcinoma (HCC) often exhibit a poor prognosis or dismal clinical outcomes due to ineffective chemotherapy or a multi-drug resistance (MDR) process. Thus, it is urgent to develop a new chemotherapeutic sensitivity testing system for HCC treatment. The presence study investigated the potential application of a novel chemotherapeutic sensitivity-testing system based on a collagen gel droplet embedded 3D–culture system (CD-DST). Methods Primary cells were separating from surgical resection specimens and then tested by CD-DST. To identify whether HCC cell lines or cells separating from clinical specimens contain MDR features, the cells were treated with an IC 50 (half maximal inhibitory concentration) or IC max (maximal inhibitory concentration) concentration of antitumor agents, e.g., 5-furuolouracil (5-FU), paclitaxel (PAC), cisplatin (CDDP), epirubicin (EPI), or oxaliplatin (L-OHP), and the inhibitory rates (IRs) were calculated. Results HepG2 cells were sensitive to 5-FU, PAC, CDDP, EPI, or L-OHP; the IC 50 value is 0.83 ± 0.45 μg/ml, 0.03 ± 0.02 μg/ml, 1.15 ± 0.75 μg/ml, 0.09 ± 0.03 μg/ml, or 1.76 ± 0.44 μg/ml, respectively. Only eight (8/26), nine (9/26), or five (5/26) patients were sensitive to the IC max concentration of CDDP, EPI, or L-OHP; whereas only three (3/26), four (4/26), or two (2/26) patients were sensitive to the IC 50 concentration of CDDP, EPI, or L-OHP. No patients were sensitive to 5-FU or PAC. Conclusions The in vitro drug sensitivity exanimation revealed the MDR features of HCC and examined the sensitivity of HCC cells from clinical specimens to anti-tumor agents. CD-DST may be a useful method to predict the potential clinical benefits of anticancer agents for HCC patients